Q4 Earnings Estimate for Annovis Bio Issued By HC Wainwright

Annovis Bio, Inc. (NYSE:ANVS) – Equities researchers at HC Wainwright decreased their Q4 2024 earnings per share (EPS) estimates for shares of Annovis Bio in a note issued to investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.38) per share for the quarter, down from their previous estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Annovis Bio’s current full-year earnings is ($1.99) per share. HC Wainwright also issued estimates for Annovis Bio’s Q1 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.76) EPS and FY2025 earnings at ($2.32) EPS.

Annovis Bio (NYSE:ANVS) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.33).

Several other brokerages have also recently weighed in on ANVS. Maxim Group raised shares of Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Friday, October 25th. EF Hutton Acquisition Co. I upgraded Annovis Bio to a “strong-buy” rating in a research report on Tuesday, August 13th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $32.17.

Annovis Bio Stock Performance

Shares of NYSE:ANVS opened at $7.41 on Thursday. The company has a market capitalization of $102.26 million, a PE ratio of -1.66 and a beta of 1.70. The company’s fifty day moving average is $8.47 and its 200-day moving average is $8.27. Annovis Bio has a 52 week low of $4.53 and a 52 week high of $22.49.

Hedge Funds Weigh In On Annovis Bio

A number of large investors have recently modified their holdings of ANVS. Greenwich Wealth Management LLC boosted its holdings in Annovis Bio by 19.9% in the second quarter. Greenwich Wealth Management LLC now owns 15,075 shares of the company’s stock valued at $87,000 after acquiring an additional 2,500 shares during the last quarter. XTX Topco Ltd acquired a new position in Annovis Bio during the 2nd quarter valued at about $115,000. Cetera Advisors LLC bought a new position in shares of Annovis Bio in the 1st quarter valued at about $122,000. Quest Partners LLC acquired a new stake in shares of Annovis Bio during the 3rd quarter worth approximately $371,000. Finally, Vanguard Group Inc. raised its stake in shares of Annovis Bio by 6.1% during the first quarter. Vanguard Group Inc. now owns 357,942 shares of the company’s stock worth $4,260,000 after buying an additional 20,588 shares during the last quarter. 15.83% of the stock is currently owned by institutional investors and hedge funds.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.